Drugs / TRS003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03882424 | Jun → Sep 2018 | — | Zhejiang Teruisi Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05378867 | Aug 2022 → Oct 2023 | colorectal cancer | Zhejiang Teruisi Pharmaceutical Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT04416035 | Aug 2020 → Oct 2021 | non-small cell lung carcinoma | Zhejiang Teruisi Pharmaceutical Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRS003 | “TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:” NCT05378867 ↗ |
| Route | Intravenous | “TRS003, 5 mg/kg IV every 14 days” NCT05378867 ↗ |